SCHEMBL207373

SCHEMBL207373

CCCCCCCCc1ccc(Nc2nc(-c3cc4ccccc4o3)cs2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 2/20 0.60
NPC1 O15118 7/20 0.58
RAB9A P51151 7/20 0.58
SMN1; SMN2 Q16637 6/20 0.58
MAPT P10636 6/20 0.58
STAT1 P42224 1/20 0.58
NFKB1 P19838 5/20 0.51
NFKB2 Q00653 5/20 0.51
RELA Q04206 5/20 0.51
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 2/20 0.51
TP53 P04637 1/20 0.50
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
GAA P10253 2/20 0.48
LMNA P02545 2/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
MCL1 Q07820 1/20 0.48
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206320 1.00 CSNK2A1 (0.60) CSNK2A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL206626 0.86 CSNK2A1 (0.58) CSNK2A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2695557 0.86 CSNK2A1 (0.58) CSNK2A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL29152961 0.81 CSNK2A1 (0.77) CSNK2A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL30723287 0.81 CSNK2A1 (0.77) CSNK2A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL207101 0.79 SMN1; SMN2 (0.53) CSNK2A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL206699 0.78 MAPT (0.63) CSNK2A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL206259 0.78 MAPT (0.63) CSNK2A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL207214 0.78 SMN1; SMN2 (0.49) CSNK2A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2700276 0.77 SMN1; SMN2 (0.48) CSNK2A1NPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 CSNK2A1 1577/4885NPC1 62/4885RAB9A 1357/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 CSNK2A1 1577/4885NPC1 62/4885RAB9A 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.